SOURCE: Bio-Matrix Scientific Group Inc.

February 25, 2010 08:00 ET

Bio-Matrix Scientific Group, Inc. Outlines Strategy for Growth in 2010 With Focus on Developing Stem Cell Related Research and Accretive Acquisitions

Company in Discussions With Several Niche Biotechnology Companies

SAN DIEGO, CA--(Marketwire - February 25, 2010) -  Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced today its growth strategy for 2010. The Company announced that it will apply its resources toward conducting stem cell related research aimed at developing and commercializing innovative new therapies. The Company also announced its intent to actively pursue strategic partnerships and acquisitions. BMSN is currently in various stages of negotiation with several niche biotechnology companies regarding joint ventures, alliances and business combinations which the Company feels will diversify potential revenue streams.

An example of the strategic synergy being developed is the recent progress made by Entest Biomedical, Inc. (OTCBB: ENTB), a publicly traded subsidiary of the Company which is pioneering the novel field of regenerative photoceuticals as applied to Chronic Obstructive Pulmonary Disease (COPD), a condition afflicting an estimated 24 million people. Last week Entest, in collaboration with leading researchers, published a peer reviewed paper outlining its ENT-576 therapeutic approach, which can be accessed at http://www.translational-medicine.com/content/pdf/1479-5876-8-16.pdf.

David Koos, the Company's Chairman & CEO, stated, "We have invested substantial efforts into developing clinical-grade cell processing procedures, protocols, and facilities. As a result of these efforts, we feel our 15,000 square foot facility is state of the art. We are now seeking to expand the use of these assets beyond conventional stem cell storage, which previously had been our core business. There are a number of potential relationships forming with companies which present unique opportunities that can be advantageous to our overall goal of establishing Bio-Matrix as a world leader in stem cell therapeutics."

A spokesperson for Bio-Matrix Scientific Group noted that further details will be discussed on the Company's Shareholder Conference Call slated for March 23, 2010. Those wishing to participate in the call are requested to email or fax their name, email address and any questions they wish addressed during the call to info@bmsn.us (email) or 619.330.2328(fax) prior to March 10, 2010. Instructions, including call in number and access codes, will be emailed to participants once details have been finalized.

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB. Entest Biomedical, Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN).

Forward-looking statements

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:
    David R. Koos
    Chairman & CEO
    Bio-Matrix Scientific Group Inc.
    619.702.1404 Direct
    619.330.2328 Fax

    www.BMSN.us
    Email Contact